Yes, migraines are significantly more common in females. Women are roughly three times more likely to experience migraines than men, with a lifetime incidence of about 43% in women compared to 18% in men. This gap is one of the largest sex-based differences in any neurological condition, and it shapes everything from how migraines are studied to how they’re treated.
The Gender Gap Starts at Puberty
The pattern isn’t straightforward from birth. Before age 12, boys actually have a slightly higher rate of migraines than girls. The two groups are roughly equal in early childhood, and if anything, boys edge ahead. That changes dramatically around puberty. By age 15, migraines are significantly more common in girls, and the gap only widens from there.
This reversal at puberty is one of the strongest clues researchers have about why the difference exists. Something about the hormonal shifts of female puberty fundamentally changes migraine susceptibility, and the effect persists for decades. The female-to-male ratio in adulthood ranges from about 3:1 to as high as 5:1 depending on the population studied.
Why Hormones Drive the Difference
The leading explanation centers on estrogen, specifically the fluctuation of estrogen levels rather than the hormone itself. Steady estrogen, whether high or low, doesn’t seem to be the problem. It’s the drop in estrogen that triggers attacks. This is why migraines so often cluster around menstruation, when estrogen falls sharply in the days before and during a period.
This “estrogen withdrawal” theory explains several patterns at once. Pregnancy, when estrogen levels rise steadily and stay high, brings relief for 60 to 70% of women, particularly in the second and third trimesters. Meanwhile, the perimenopausal transition, when estrogen swings unpredictably before its final decline, is one of the worst periods for migraine. About 30% of women hit a peak in migraine symptoms during perimenopause, and 60 to 70% of perimenopausal women report headaches among their symptoms.
There’s also evidence that testosterone may be protective. Chronic pain conditions across the board are diagnosed more often in women, and researchers believe androgens play a dampening role in pain signaling. This would help explain why boys lose their slight migraine edge once testosterone levels rise at puberty while girls, gaining estrogen cycles instead, become more vulnerable.
Menstrual Migraine as a Distinct Pattern
Menstrual migraine is a recognized subtype that affects only people who menstruate. Attacks occur within a five-day window around the start of a period (from two days before to three days after day one of bleeding). Some women get migraines only during this window, which is classified as pure menstrual migraine. Others get attacks during this window and at other times in their cycle, known as menstrually related migraine. Both forms tend to be more disabling and harder to treat than migraines that occur without any menstrual link.
The trigger applies to any source of cyclical hormonal withdrawal, not just natural periods. Women using combined oral contraceptives or cyclical hormone replacement therapy can experience the same pattern during the hormone-free interval, when exogenous estrogen drops.
How Migraines Change After Menopause
Once estrogen levels stabilize at their post-menopausal baseline, the news is generally good. Migraine without aura tends to improve after menopause, and some women experience complete relief. The stabilization of hormones, even at low levels, removes the repeated withdrawal trigger that drove attacks for years.
The picture is more complicated for migraine with aura. This subtype can actually worsen after menopause or even appear for the first time. Some post-menopausal women develop episodes of aura without any headache at all. And for a smaller but meaningful percentage of women, migraines persist through menopause and resist standard pain relief. The trajectory isn’t guaranteed, but the overall trend is toward improvement once hormonal fluctuations end.
Structural Brain Differences Between Male and Female Migraineurs
The sex difference isn’t just hormonal. Brain imaging studies have found that women with migraines show measurably thicker cortex in several brain regions compared to men with migraines and compared to healthy people of either sex. The areas affected include the posterior insula, which processes pain and body awareness, and the precuneus, involved in integrating sensory information.
These structural differences come with functional ones. In women with migraines, the thickened posterior insula shows stronger connections to areas responsible for touch perception, emotional processing, and memory. The precuneus connects more strongly to the amygdala, a region central to emotional responses and threat detection. These enhanced connections aren’t found in male migraineurs, which suggests that the female brain may process migraine pain through a more emotionally and sensorially amplified network. Whether these differences are a cause or consequence of repeated migraine attacks remains an open question.
The Disability Burden Falls Heaviest on Young Women
Migraine ranks as the second leading cause of disability worldwide. For women between ages 15 and 49, it ranks first. That age range covers the peak reproductive years, which aligns perfectly with the period of greatest hormonal fluctuation. The practical consequences are enormous: lost workdays, disrupted education, reduced quality of life, and years spent managing a condition that cycles relentlessly.
Women are also more likely to report migraine-related disabilities than men, which may reflect both higher attack frequency and differences in how the female brain processes migraine pain.
Treatment May Work Differently by Sex
Despite the overwhelming female predominance of migraine, surprisingly few clinical trials analyze their results separately by sex. A recent review of 25 published trials on newer migraine prevention drugs (antibodies targeting a pain signaling molecule called CGRP) found that only two included a sex-based analysis of their primary outcome. Most trials enroll a majority of women but report only combined results.
The limited data that does exist hints at meaningful differences. One evaluation found that certain acute migraine treatments targeting CGRP receptors appeared effective only in women, while preventive antibodies targeting the same system worked for both sexes. This is a significant gap in medical knowledge. If treatments work differently depending on the patient’s sex, current one-size-fits-all prescribing may be leaving some patients undertreated.